I think you are correct. Quote from March 5th C
Post# of 148282
Quote from March 5th CC, Dr Lalezari:
"I am pleased to announce that we are moving forward with the submission of four manuscripts in the coming weeks, including two papers with data from women with Triple Negative Breast Cancer, a paper in patients with Multi-Drug Resisting HIV and a paper in patients with mild to moderate Covid-19."
Question: Does he mean he is submitting these papers to another entity to conduct a peer review, or does he mean they have been peer-reviewed and they will be published?
He continues in the next paragraph:
The first publication will report on the observation that eight of ten women with parablind therapy for Triple Negative Breast Cancer had either stable disease or a partial response after six months of combined treatment of Leronlimab with a chemotherapy agent called Carboplatin. This result compares favorably with historical controls."
Source: Transcript of Conference call March 5, 2024 per DJknows #141518
This transcript contains a trove of information about the coming events.